We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UnitedHealth's Misdiagnosis: Can Berkshire's Bet Spark a Recovery?
Read MoreHide Full Article
Key Takeaways
UnitedHealth's cost ratio averaged 87.1% in 1H25 and may near 89.4% by year-end, eroding margins.
EPS outlook was slashed to at least $16, with earnings growth unlikely before 2026.
Berkshire's 5M-share purchase fueled buying, but UNH still trades 39.7% lower year to date.
UnitedHealth Group Incorporated (UNH - Free Report) remains under heavy pressure after severely underestimating medical cost trends, a misstep that has eroded margins and rattled investors. Management has admitted to the problem, with expenses spiraling far faster than expected. Medical costs surged nearly 16% in the first half of 2025, following a 9.2% rise in 2024. The cost ratio — a measure of how much premium revenue goes to paying claims — climbed from 83.2% in 2023 to 85.5% in 2024, averaged 87.1% in the 1H25, and could approach 89.4% by year-end. The higher the ratio, the less profit UnitedHealth retains.
The strain has already shown up in earnings. UNH missed estimates in both quarters this year and cut its EPS outlook from $26–$26.50 at one time to at least $16. Adding to the drama, former CEO Stephen Hemsley returned to lead the company, replacing Andrew Witty, and management warned that earnings growth may not resume until 2026.
Yet, in the middle of this turmoil, UnitedHealth attracted an influential backer. Warren Buffett’s Berkshire Hathaway Inc. (BRK.B - Free Report) disclosed a purchase of more than 5 million shares, a stake worth roughly $1.57 billion. It immediately triggered copycat buying from institutions and retail investors, reinforcing the perception that UNH’s beaten-down valuation offers long-term appeal.
Still, short-term risks loom large. UnitedHealth is facing $1.6 billion in potential settlement costs. Its Medicare Advantage billing practices are under criminal investigation by the DOJ. With legal scrutiny, public criticism, regulatory risks associated with PBMs and rising utilization trends, a true recovery may remain out of reach, at least for now.
How are Centene & Elevance Faring?
UnitedHealth’s peers are also reeling from surging medical costs, forcing guidance cuts for 2025. Centene Corporation (CNC - Free Report) slashed its adjusted EPS outlook to $1.75, down from $7.25, and now projects its HBR to spike to 93.5% in the second half versus 89.4% last year. Still, Centene expects premium and service revenues to climb to $172 billion. Elevance Health, Inc. (ELV - Free Report) reduced its adjusted EPS forecast to $30, below the prior $34.15–$34.85 range. Its benefit expense ratio is set to hit 90% in 2025, though operating cash flow should rise to $6 billion.
UnitedHealth’s Price Performance, Valuation and Estimates
Even after the Berkshire-driven bounce, UNH shares are still down 39.7% year to date, steeper than the industry’s 30.8% decline.
Image Source: Zacks Investment Research
From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 17.87, still up from the industry average of 14.96. UNH carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for UnitedHealth’s 2025 earnings is pegged at $16.21 per share, implying a 41.4% drop from the year-ago period.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #5 (Strong Sell).
Image: Bigstock
UnitedHealth's Misdiagnosis: Can Berkshire's Bet Spark a Recovery?
Key Takeaways
UnitedHealth Group Incorporated (UNH - Free Report) remains under heavy pressure after severely underestimating medical cost trends, a misstep that has eroded margins and rattled investors. Management has admitted to the problem, with expenses spiraling far faster than expected. Medical costs surged nearly 16% in the first half of 2025, following a 9.2% rise in 2024. The cost ratio — a measure of how much premium revenue goes to paying claims — climbed from 83.2% in 2023 to 85.5% in 2024, averaged 87.1% in the 1H25, and could approach 89.4% by year-end. The higher the ratio, the less profit UnitedHealth retains.
The strain has already shown up in earnings. UNH missed estimates in both quarters this year and cut its EPS outlook from $26–$26.50 at one time to at least $16. Adding to the drama, former CEO Stephen Hemsley returned to lead the company, replacing Andrew Witty, and management warned that earnings growth may not resume until 2026.
Yet, in the middle of this turmoil, UnitedHealth attracted an influential backer. Warren Buffett’s Berkshire Hathaway Inc. (BRK.B - Free Report) disclosed a purchase of more than 5 million shares, a stake worth roughly $1.57 billion. It immediately triggered copycat buying from institutions and retail investors, reinforcing the perception that UNH’s beaten-down valuation offers long-term appeal.
Still, short-term risks loom large. UnitedHealth is facing $1.6 billion in potential settlement costs. Its Medicare Advantage billing practices are under criminal investigation by the DOJ. With legal scrutiny, public criticism, regulatory risks associated with PBMs and rising utilization trends, a true recovery may remain out of reach, at least for now.
How are Centene & Elevance Faring?
UnitedHealth’s peers are also reeling from surging medical costs, forcing guidance cuts for 2025. Centene Corporation (CNC - Free Report) slashed its adjusted EPS outlook to $1.75, down from $7.25, and now projects its HBR to spike to 93.5% in the second half versus 89.4% last year. Still, Centene expects premium and service revenues to climb to $172 billion. Elevance Health, Inc. (ELV - Free Report) reduced its adjusted EPS forecast to $30, below the prior $34.15–$34.85 range. Its benefit expense ratio is set to hit 90% in 2025, though operating cash flow should rise to $6 billion.
UnitedHealth’s Price Performance, Valuation and Estimates
Even after the Berkshire-driven bounce, UNH shares are still down 39.7% year to date, steeper than the industry’s 30.8% decline.
From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 17.87, still up from the industry average of 14.96. UNH carries a Value Score of B.
The Zacks Consensus Estimate for UnitedHealth’s 2025 earnings is pegged at $16.21 per share, implying a 41.4% drop from the year-ago period.
The stock currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.